NTC is an international pharmaceutical Group headquartered in Milan, Italy, known for its strong focus on research and development (R&D). The Group collaborates with distributors and partners in over 100 countries worldwide to research, develop, register, and commercialize innovative drugs, medical devices, and food supplements in ophthalmology, and other therapeutic areas - gastro-metabolism, gynecology, and pediatrics.

NTC directly promotes its ophthalmology solutions in Italy and Spain through its dedicated field forces. The contact with healthcare professionals allows the Group to better understand the unmet medical needs and gather valuable insights that help refine its therapeutic solutions according to patients’ needs.

NTC is owned by private equity funds, including Wise Equity SGR S.p.A., Unigestion GP S.à.r.l., and Racer S.r.l.

Key milestones in NTC's history

Our strategy

A program centered on the therapeutic gesture that connects the world of medicine with the care experience.

At NTC, we envision a model of care that empowers individuals to achieve autonomy and balance in their health. Guided by the latest directives from the World Health Organization (WHO), we embrace a One Health approach, promoting ethical consumption practices. This not only enhances the sustainability of medicine but also ensures safety, simplicity, and ease of use.

A central aspect of our mission is to promote the rational use of antibiotics. This is a key component of NTC's strategy to improve global health outcomes and reduce the societal burden posed by antibiotic resistance.